1801 Augustine Cut-Off
662 articles with Incyte Corporation
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
Incyte announced that the U.S. Food and Drug Administration has issued a complete response letter for ruxolitinib extended-release tablets, a JAK1/JAK2 inhibitor, for once-daily use in the treatment of certain types of myelofibrosis, polycythemia vera and graft-versus-host disease.
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz™ (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
An advisory committee will meet March 22 to discuss the fate of Biogen and Ionis’ ALS hopeful tofersen. For that and more, see inside.
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
Incyte announced new 104-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Opzelura® cream 1.5% in patients 12 years of age and older with nonsegmental vitiligo, a chronic autoimmune disease characterized by depigmentation of skin.
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
Incyte announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib, an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.
Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline
Caris Life Sciences today announced a strategic research partnership with Incyte Corporation (NASDAQ:INCY) to augment precision medicine approaches for Incyte's oncology pipeline.
Incyte Corporation’s Phase III LIMBER-304 clinical trial has come to an end following a third-party investigation that forecasted poor results.
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
Incyte announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology Annual Meeting, held March 17-21, 2023, in New Orleans.
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
Incyte announced that it will discontinue the Phase 3 LIMBER-304 trial following results of a pre-planned interim analysis conducted by an independent data monitoring committee indicating that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents.
Incyte to Present at Upcoming Investor Conference - February 16, 2023
Incyte announced that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 11:10 a.m. in Boston.
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS).
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs.
Incyte to Present at Upcoming Investor Conference - January 24, 2023
Incyte (Nasdaq:INCY) announced today that it will present at the Guggenheim Healthcare Talks l Oncology Day on Wednesday, February 8, 2023 at 1:35 p.m. (EST) in New York.
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 7, 2023.
NOTICE TO DISREGARD -- China Medical System Holdings Ltd.
We are advised by China Medical System Holdings Ltd. that journalists and other readers should disregard the news release, "CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient" issued December 6, 2022, over GlobeNewswire.
Incyte to Present at Upcoming Investor Conferences - December 15, 2022
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January.
Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
Incyte announced new research detailing the development and mechanism of action of INCA033989, an Incyte-discovered, investigational novel anti-mutant calreticulin -targeted monoclonal antibody.
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
Incyte announced new data from two of its LIMBER trials evaluating monotherapy and combination strategies using ruxolitinib with parsaclisib, its investigational phosphatidylinositol 3-kinase delta inhibitor, and INCB00928, its activin receptor-like kinase inhibitor, in patients with myelofibrosis.